GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical significance ...read more
Growth Capitalist (https://growthcapitalist.com/2016/09/gw-pharmas-epidiolex-achieves-statistical-significance-in-third-phase-3-trial-for-treatment-of-rare-pediatric-epilepsy/)
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome – Primary endpoint achieved in both Epidiolex doses with high statistical significance ...read more